Skip to main content
Journal cover image

Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.

Publication ,  Journal Article
Polascik, TJ; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Mouraviev, V
Published in: Prostate
September 15, 2008

BACKGROUND: Early detection of small volume prostate cancer (PCa) has led to the concept of focal therapy to treat in an organ-sparing manner. We evaluated trends in pathologic staging among patients with localized PCa undergoing radical prostatectomy (RP), defining the frequency of unilateral cancers during 1988-1995, 1996-2000 and 2001-2006. METHODS: Data were abstracted from the Duke Prostate Cancer Outcome database selecting 3,676 men with available pathology treated with RP. Based on surgical pathology, trends in as pathological T (pT) stage, pathological Gleason Score (pGS), and percent tumor involvement (PTI) were evaluated. RESULTS: pT2a increased from 2.8% of men undergoing RP in 1988-1995 to 13.0% during 2001-2006 (P < 0.0005). PTI analysis shifted towards low volume disease, e.g. PTI

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate

DOI

EISSN

1097-0045

Publication Date

September 15, 2008

Volume

68

Issue

13

Start / End Page

1380 / 1386

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Multivariate Analysis
  • Middle Aged
  • Mass Screening
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Polascik, T. J., Mayes, J. M., Sun, L., Madden, J. F., Moul, J. W., & Mouraviev, V. (2008). Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate, 68(13), 1380–1386. https://doi.org/10.1002/pros.20804
Polascik, Thomas J., Janice M. Mayes, Leon Sun, John F. Madden, Judd W. Moul, and Vladimir Mouraviev. “Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.Prostate 68, no. 13 (September 15, 2008): 1380–86. https://doi.org/10.1002/pros.20804.
Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008 Sep 15;68(13):1380–6.
Polascik, Thomas J., et al. “Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.Prostate, vol. 68, no. 13, Sept. 2008, pp. 1380–86. Pubmed, doi:10.1002/pros.20804.
Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008 Sep 15;68(13):1380–1386.
Journal cover image

Published In

Prostate

DOI

EISSN

1097-0045

Publication Date

September 15, 2008

Volume

68

Issue

13

Start / End Page

1380 / 1386

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Multivariate Analysis
  • Middle Aged
  • Mass Screening
  • Male